(Q37779101)

English

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

scientific article published on September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 August 2017

1 reference

Europe PubMed Central

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? (English)

1 reference

Europe PubMed Central

23 August 2017

Alzheimer's disease

0 references

0 references

0 references

0 references

author name string

Nigel Irwin

1

1 reference

Europe PubMed Central

23 August 2017

Victor Gault

2

1 reference

Europe PubMed Central

23 August 2017

Peter R Flatt

3

1 reference

Europe PubMed Central

23 August 2017

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

23 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

23 August 2017

19

1 reference

Europe PubMed Central

23 August 2017

9

1 reference

Europe PubMed Central

23 August 2017

1039-1048

1 reference

Europe PubMed Central

23 August 2017

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Therapeutic potential for GIP receptor agonists and antagonists.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Extrapancreatic effects of GIP and GLP-1.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Molecular mechanisms underlying nutrient-stimulated incretin secretion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Molecular mechanisms underlying nutrient detection by incretin-secreting cells

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-beta release from MG-63 cells.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Impact of glucose-dependent insulinotropic peptide on age-induced bone loss

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Gastric inhibitory polypeptide (GIP) binding sites in rat brain.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Effects of glucose-dependent insulinotropic peptide on behavior

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

GIP biology and fat metabolism

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Vaccination against GIP for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

RS4-type resistant starch prevents high-fat diet-induced obesity via increased hepatic fatty acid oxidation and decreased postprandial GIP in C57BL/6J mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.513381

21 January 2018

Identifiers

10.1517/13543784.2010.513381

1 reference

Europe PubMed Central

23 August 2017

1 reference

Europe PubMed Central

23 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37779101&oldid=2090679418"